Gefapixant Citrate

N/A

Report date: 2022/01/26 11:16:49
NME

Base Information

Drug NameGefapixant Citrate
Drug Alias NameGefapixantゲーファピキサントクエン酸塩LyfnuaAF-219R-1646 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP2X purinoceptor 3 antagonists
TargetsP2X purinoceptor 3
Therapy Area/IndicationsPainEndometriosisCystitis, Interstitial +[9] 
Global Approved IndicationsCough
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/01/20
Country/TerritoryCzechiaBelgiumCanada +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme BvMerck Sharp & Dohme LLC +[5] 
Inactive CompaniesAfferent Pharmaceuticals Inc
Active IndicationsCough
Inactive IndicationsPainEndometriosisCystitis, Interstitial +[8] 

Other Information

ATC CodeL01DB
Related LinksWikipediaDrugBankKEGG